NCT05314738 Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus
| NCT ID | NCT05314738 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Glaukos Corporation |
| Condition | Progressive Keratoconus |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2022-03-08 |
| Primary Completion | 2025-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 150 participants in total. It began in 2022-03-08 with a primary completion date of 2025-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.
Eligibility Criteria
Inclusion Criteria: * Provide written informed consent * Ability to hold gaze sufficiently stable for study testing * Willingness and ability to follow all instructions and comply with schedule for follow-up visits * Have a diagnosis of keratoconus Exclusion Criteria: * Known allergy or sensitivity to the test articles or components * Any disease causing abnormal topography other than keratoconus * Prior or current ocular condition (other than keratoconus) in the study eye that may predispose the eye for future complications
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05314738 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Progressive Keratoconus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05314738 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05314738 currently recruiting?
Yes, NCT05314738 is actively recruiting participants. Contact the research team at marmijo@glaukos.com for enrollment information.
Where is the NCT05314738 trial being conducted?
This trial is being conducted at Dothan, United States, Teaneck, United States, Westerville, United States.
Who is sponsoring the NCT05314738 clinical trial?
NCT05314738 is sponsored by Glaukos Corporation. The trial plans to enroll 150 participants.